¼¼°èÀÇ Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ - Ä¡·áº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
Hairy Cell Leukemia Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå
:
1554171
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2024³â 08¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 70 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :
Grand View Research, Inc.ÀÇ Á¶»ç º¸°í¼¿¡ µû¸£¸é, ¼¼°è Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 1¾ï 4,770¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̰í, ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 5.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÀÌ ¼ºÀåÀÇ ¿øµ¿·ÂÀº ƯÈ÷ °í·ÉÈ »çȸ¿¡¼ Åм¼Æ÷ ¹éÇ÷º´(HCL)ÀÇ ÀÌȯÀ²ÀÇ »ó½ÂÀ̸ç, À̷νá È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Ç¥Àû Ä¡·áÁ¦¿Í ´ÜŬ·ÐÇ×ü¿Í °°Àº ½Å±Ô Ä¡·áÁ¦ÀÇ µµÀÔÀº Ä¡·á ¿É¼ÇÀ» Å©°Ô È®´ëÇϰí, ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí, ½ÃÀå ¼ºÀåÀ» ´õ¿í °ÈÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¼±ÁøÁö¿ª¿¡¼ÀÇ ÀÎÁöµµ Çâ»ó°ú °í±Þ ÀÇ·á ÀÎÇÁ¶óÀÇ Á¤ºñµµ ȯÀÚ°¡ ÃֽŠġ·á ¿É¼Ç¿¡ Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï Çϱâ À§ÇØ HCL Ä¡·áÀÇ Ã¤¿ëÀ» ÃËÁøÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
ÀÓ»ó½ÃÇèÀº BRAF ¾ïÁ¦Á¦¿Í MEK ¾ïÁ¦Á¦¿Í °°Àº º´¿ë ¿ä¹ýÀÌ Ä¡·á È¿°ú¸¦ Å©°Ô Çâ»ó½ÃŰ´Â °ÍÀ¸·Î ³ªÅ¸³µÀ¸¸ç, HCL ȯÀÚ¿¡°Ô »õ·Î¿î Èñ¸ÁÀ» °¡Á®¿Ô½À´Ï´Ù. ¶ÇÇÑ, ÇöÀç ÁøÇà ÁßÀÎ ¸ÂÃãÇü ÀÇ·á ¿¬±¸´Â °³º° ȯÀÚÇÁ·ÎÆÄÀÏ¿¡ ¸Â°Ô Ä¡·á¸¦ Á¶Á¤ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϸç, ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈÇÏ¸é¼ Ä¡·á ¼ºÀûÀ» °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº °¢ ȯÀÚ °íÀ¯ÀÇ ¿ä±¸¿¡ ´ëÀÀÇÏ°íº¸´Ù È¿°úÀûÀÌ°í ¾ÈÀüÇÑ Ä¡·á¹ýÀ¸·Î À̾îÁö±â ¶§¹®¿¡ ƯÈ÷ À¯¸ÁÇÕ´Ï´Ù.
2023³â 9¿ù ¹Ì±¹ ±¹¸³ÀÇÇÐ µµ¼°ü¿¡¼ ¹ßÇ¥µÈ ¿¬±¸´Â °íÀüÀûÀÎ HCLÀÇ ÀÓ»óÀû Ư¡¿¡ ´ëÇÑ Ãß°¡ ÀλçÀÌÆ®À» Á¦°øÇÕ´Ï´Ù. ÀÌ ¿¬±¸´Â ºñÀåÁ¾ÀÌ ¸ðµç ȯÀÚÀÇ °¡Àå ÈçÇÑ ÀÓ»ó Æ¯Â¡(100%)À̾ú½À´Ï´Ù°í º¸°íÇÕ´Ï´Ù. ´Ù¸¥ Áß¿äÇÑ ¼Ò°ßÀ¸·Î´Â 75% ȯÀÚ¿¡¼ °£Á¾´ë, 58.33% ȯÀÚ¿¡¼ ¹üÇ÷±¸ °¨¼Ò°¡ º¸¿´°í ³ª¸ÓÁö ȯÀÚ´Â ÀÌÇ÷±¸ °¨¼Ò¸¦ º¸¿´½À´Ï´Ù. ȯÀÚÀÇ 66.6% ¸»ÃÊ Ç÷¾× µµ¸» Ç¥º»(PBS)¿¡¼´Â À¯¸ð¼¼Æ÷°¡ °üÂûµÇ¾ú°í, °ñ¼öÈíÀÎ(BMA)¿¡¼´Â 25%ÀÇ °æ¿ì µå¶óÀÌÅÇÀÌ °üÂûµÇ¾ú½À´Ï´Ù. °ñ¼ö õÀÚ »ý°Ë ¼Ò°ß¿¡¼´Â 92%ÀÇ È¯ÀÚ¿¡¼ °í¼¼Æ÷¼ºÀ̾ú°í, ±ØÈ÷ ÀϺÎ(8%)¿¡¼ Àú¼¼Æ÷¼ºÀ» º¸¿´½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ß°ßÀº HCLÀÇ º¹À⼺À» °Á¶ÇÏ´Â °ÍÀ̸ç, ƯÈ÷ÀÌ Áúº´ÀÇ ´Ù¾çÇÑ Áõ»ó°ú Áø´Ü ¹× °ü¸®ÀÇ °úÁ¦¸¦ °í·ÁÇÒ ¶§ Ä¡·á Á¢±Ù¹ýÀÇ Áö¼ÓÀûÀÎ ¿¬±¸¿Í Çõ½ÅÀÇ Çʿ伺À» °Á¶ÇÕ´Ï´Ù.
Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- Ç¥Àû Ä¡·á ºÎ¹®Àº 2023³â¿¡ 32.45%ÀÇ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ µ¿¾È 7.5%ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) °¡Àå ºü¸¥ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
- º´¿ø ºÎ¹®Àº 2023³â 64.34%ÀÇ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. º´¿øÀº HCLÀÇ È¿°úÀûÀÎ Ä¡·á¿¡ ÇʼöÀûÀÎ Á¾¾ç Àü¹® ÀǷḦ Æ÷ÇÔÇÑ Á¾ÇÕÀûÀÎ ¼ºñ½º¸¦ Á¦°øÇϱ⠶§¹®ÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
- ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
Á¦4Àå Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀå : Ä¡·áº° ÃßÁ¤ ¹× µ¿Ç⠺м®
- Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀå : Ä¡·á ´ë½Ãº¸µå
- Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀå : Ä¡·á º¯µ¿ ºÐ¼®
- Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀå : Ä¡·á ¼öÀÍ
- ÈÇпä¹ý
- Ç¥Àû¿ä¹ý
- ¸é¿ª¿ä¹ý
- ±âŸ
Á¦5Àå Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®
- Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀå : ÃÖÁ¾ ¿ëµµ ´ë½Ãº¸µå
- Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
- Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀå : ÃÖÁ¾ ¿ëµµ ¼öÀÍ
- º´¿ø
- Àü¹® Ŭ¸®´Ð
- ±âŸ
Á¦6Àå Åм¼Æ÷ ¹éÇ÷º´ Ä¡·á ½ÃÀå :Áö¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®, Ä¡·áº°, ÃÖÁ¾ ¿ëµµº°
- Áö¿ª ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø µ¿Ç⠺м®(2018³â-2030³â)
- ºÏ¹Ì
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦7Àå °æÀï ±¸µµ
- ±â¾÷/°æÀïÀÇ ºÐ·ù
- º¥´õ »óȲ
- ÁÖ¿ä ¸®¼¿·¯ ¹× ä³Î ÆÄÆ®³Ê ¸ñ·Ï
- ÁÖ¿ä °í°´
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
- ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Pfizer Inc
- F. Hoffmann La Roche AG
- Janssen Global Services
- Emcure Pharmaceuticals
- Dr. Reddy's Laboratories
- Amgen, Inc.
- Hospira
- AbbVie
- AstraZeneca
BJH
¿µ¹® ¸ñÂ÷
Hair Cell Leukemia Treatment Market Growth & Trends:
The global hairy cell leukemia treatment market size is estimated to reach USD 147.7 million by 2030, growing at a CAGR of 5.4% during the forecast period, according to a report by Grand View Research, Inc. This growth is driven by the rising incidence of hairy cell leukemia (HCL), particularly among aging populations, which increases the demand for effective treatments. The introduction of novel therapeutics, such as targeted therapies and monoclonal antibodies, has significantly expanded treatment options, improving patient outcomes and further fueling market growth. Enhanced awareness and the availability of advanced healthcare infrastructure, especially in developed regions, also play a crucial role in driving the adoption of HCL treatments, ensuring that patients can access the latest therapeutic options.
Clinical trials have shown that combination therapies, such as BRAF and MEK inhibitors, can significantly enhance treatment efficacy, offering new hope for patients with HCL. Moreover, ongoing research into personalized medicine aims to tailor treatments to individual patient profiles, potentially improving outcomes while minimizing side effects. This approach is particularly promising as it addresses each patient's unique needs, leading to more effective and safer therapies.
A study published by the National Library of Medicine in September 2023 provides further insights into the clinical features of classical HCL. The study reported that splenomegaly was all patients' most common clinical feature (100%). Other significant findings included hepatomegaly in 75% of patients and pancytopenia in 58.33%, with the remaining patients exhibiting bicytopenia. Hairy cells were observed in the peripheral blood smear (PBS) of 66.6% of patients, while bone marrow aspirates (BMA) resulted in a dry tap in 25% of cases. Bone marrow trephine biopsy findings indicated hypercellularity in 92% of patients, with a small percentage (8%) showing hypocellularity. These findings underscore the complexity of HCL and the necessity for continued research and innovation in treatment approaches, particularly in light of the disease's varied presentations and challenges in diagnosis and management.
Hairy Cell Leukemia Treatment Market Report Highlights:
- The targeted therapy segment held the largest share of 32.45% in 2023 and is also expected to grow at the fastest CAGR of 7.5% during the forecast period
- The hospitals segment held the largest share of 64.34% in 2023 as they provide a comprehensive range of services, including specialized oncology care, which is crucial for the effective treatment of HCL
- Some of the prominent players in market are Pfizer Inc; F. Hoffmann La Roche AG; Janssen Global Services; Emcure Pharmaceuticals; Dr. Reddy's Laboratories; Amgen, Inc.; Hospira; AbbVie; AstraZeneca
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Treatment
- 1.2.2. End Use
- 1.2.3. Regional scope
- 1.2.4. Estimates and forecast timeline.
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database.
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Treatment Outlook
- 2.2.2. End Use Outlook
- 2.2.3. Regional Outlook
- 2.3. Competitive Insights
Chapter 3. Hairy Cell Leukemia Treatment Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising Prevalence Of Hairy Cell Leukemia
- 3.2.1.2. Advancements In Targeted Therapies
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High Treatment Costs
- 3.2.2.2. Lack of Awareness and Diagnostic Challenges
- 3.3. Hairy Cell Leukemia Treatment Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.3. Pipeline Analysis
Chapter 4. Hairy Cell Leukemia Treatment Market: Treatment Estimates & Trend Analysis
- 4.1. Hairy Cell Leukemia Treatment Market: Treatment Dashboard
- 4.2. Hairy Cell Leukemia Treatment Market: Treatment Movement Analysis
- 4.3. Hairy Cell Leukemia Treatment Market by Treatment, Revenue (USD Million)
- 4.4. Chemotherapy
- 4.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.5. Targeted Therapy
- 4.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.6. Immunotherapy
- 4.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.7. Other
- 4.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
Chapter 5. Hairy Cell Leukemia Treatment Market: End Use Estimates & Trend Analysis
- 5.1. Hairy Cell Leukemia Treatment Market: End Use Dashboard
- 5.2. Hairy Cell Leukemia Treatment Market: End Use Movement Analysis
- 5.3. Hairy Cell Leukemia Treatment Market by End Use, Revenue (USD Million)
- 5.4. Hospitals
- 5.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 5.5. Specialty Clinics
- 5.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 5.6. Others
- 5.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
Chapter 6. Hairy Cell Leukemia Treatment Market: Regional Estimates & Trend Analysis, By Treatment, and By End Use
- 6.1. Regional Dashboard
- 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
- 6.3. North America
- 6.3.1. U.S.
- 6.3.1.1. Key country dynamics
- 6.3.1.2. Regulatory framework/ reimbursement structure
- 6.3.1.3. Competitive scenario
- 6.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
- 6.3.2. Canada
- 6.3.2.1. Key country dynamics
- 6.3.2.2. Regulatory framework/ reimbursement structure
- 6.3.2.3. Competitive scenario
- 6.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
- 6.3.3. Mexico
- 6.3.3.1. Key country dynamics
- 6.3.3.2. Regulatory framework/ reimbursement structure
- 6.3.3.3. Competitive scenario
- 6.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
- 6.4. Europe
- 6.4.1. UK
- 6.4.1.1. Key country dynamics
- 6.4.1.2. Regulatory framework/ reimbursement structure
- 6.4.1.3. Competitive scenario
- 6.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
- 6.4.2. Germany
- 6.4.2.1. Key country dynamics
- 6.4.2.2. Regulatory framework/ reimbursement structure
- 6.4.2.3. Competitive scenario
- 6.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
- 6.4.3. France
- 6.4.3.1. Key country dynamics
- 6.4.3.2. Regulatory framework/ reimbursement structure
- 6.4.3.3. Competitive scenario
- 6.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
- 6.4.4. Italy
- 6.4.4.1. Key country dynamics
- 6.4.4.2. Regulatory framework/ reimbursement structure
- 6.4.4.3. Competitive scenario
- 6.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
- 6.4.5. Spain
- 6.4.5.1. Key country dynamics
- 6.4.5.2. Regulatory framework/ reimbursement structure
- 6.4.5.3. Competitive scenario
- 6.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
- 6.4.6. Norway
- 6.4.6.1. Key country dynamics
- 6.4.6.2. Regulatory framework/ reimbursement structure
- 6.4.6.3. Competitive scenario
- 6.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
- 6.4.7. Sweden
- 6.4.7.1. Key country dynamics
- 6.4.7.2. Regulatory framework/ reimbursement structure
- 6.4.7.3. Competitive scenario
- 6.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
- 6.4.8. Denmark
- 6.4.8.1. Key country dynamics
- 6.4.8.2. Regulatory framework/ reimbursement structure
- 6.4.8.3. Competitive scenario
- 6.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
- 6.5. Asia Pacific
- 6.5.1. Japan
- 6.5.1.1. Key country dynamics
- 6.5.1.2. Regulatory framework/ reimbursement structure
- 6.5.1.3. Competitive scenario
- 6.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
- 6.5.2. China
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Regulatory framework/ reimbursement structure
- 6.5.2.3. Competitive scenario
- 6.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
- 6.5.3. India
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Regulatory framework/ reimbursement structure
- 6.5.3.3. Competitive scenario
- 6.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
- 6.5.4. Australia
- 6.5.4.1. Key country dynamics
- 6.5.4.2. Regulatory framework/ reimbursement structure
- 6.5.4.3. Competitive scenario
- 6.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
- 6.5.5. South Korea
- 6.5.5.1. Key country dynamics
- 6.5.5.2. Regulatory framework/ reimbursement structure
- 6.5.5.3. Competitive scenario
- 6.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
- 6.5.6. Singapore
- 6.5.6.1. Key country dynamics
- 6.5.6.2. Regulatory framework/ reimbursement structure
- 6.5.6.3. Competitive scenario
- 6.5.6.4. Singapore market estimates and forecasts 2018 - 2030 (USD Million)
- 6.6. Latin America
- 6.6.1. Brazil
- 6.6.1.1. Key country dynamics
- 6.6.1.2. Regulatory framework/ reimbursement structure
- 6.6.1.3. Competitive scenario
- 6.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
- 6.6.2. Argentina
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Regulatory framework/ reimbursement structure
- 6.6.2.3. Competitive scenario
- 6.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
- 6.7. MEA
- 6.7.1. South Africa
- 6.7.1.1. Key country dynamics
- 6.7.1.2. Regulatory framework/ reimbursement structure
- 6.7.1.3. Competitive scenario
- 6.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
- 6.7.2. Saudi Arabia
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Regulatory framework/ reimbursement structure
- 6.7.2.3. Competitive scenario
- 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
- 6.7.3. UAE
- 6.7.3.1. Key country dynamics
- 6.7.3.2. Regulatory framework/ reimbursement structure
- 6.7.3.3. Competitive scenario
- 6.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
- 6.7.4. Kuwait
- 6.7.4.1. Key country dynamics
- 6.7.4.2. Regulatory framework/ reimbursement structure
- 6.7.4.3. Competitive scenario
- 6.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Company/Competition Categorization
- 7.2. Vendor Landscape
- 7.2.1. List of key distributors and channel partners
- 7.2.2. Key customers
- 7.2.3. Key company market share analysis, 2023
- 7.3. Company Profiles
- 7.3.1. Pfizer Inc
- 7.3.1.1. Company overview
- 7.3.1.2. Financial performance
- 7.3.1.3. Product benchmarking
- 7.3.1.4. Strategic initiatives
- 7.3.2. F. Hoffmann La Roche AG
- 7.3.2.1. Company overview
- 7.3.2.2. Financial performance
- 7.3.2.3. Product benchmarking
- 7.3.2.4. Strategic initiatives
- 7.3.3. Janssen Global Services
- 7.3.3.1. Company overview
- 7.3.3.2. Financial performance
- 7.3.3.3. Product benchmarking
- 7.3.3.4. Strategic initiatives
- 7.3.4. Emcure Pharmaceuticals
- 7.3.4.1. Company overview
- 7.3.4.2. Financial performance
- 7.3.4.3. Product benchmarking
- 7.3.4.4. Strategic initiatives
- 7.3.5. Dr. Reddy's Laboratories
- 7.3.5.1. Company overview
- 7.3.5.2. Financial performance
- 7.3.5.3. Product benchmarking
- 7.3.5.4. Strategic initiatives
- 7.3.6. Amgen, Inc.
- 7.3.6.1. Company overview
- 7.3.6.2. Financial performance
- 7.3.6.3. Product benchmarking
- 7.3.6.4. Strategic initiatives
- 7.3.7. Hospira
- 7.3.7.1. Company overview
- 7.3.7.2. Financial performance
- 7.3.7.3. Product benchmarking
- 7.3.7.4. Strategic initiatives
- 7.3.8. AbbVie
- 7.3.8.1. Company overview
- 7.3.8.2. Financial performance
- 7.3.8.3. Product benchmarking
- 7.3.8.4. Strategic initiatives
- 7.3.9. AstraZeneca
- 7.3.9.1. Company overview
- 7.3.9.2. Financial performance
- 7.3.9.3. Product benchmarking
- 7.3.9.4. Strategic initiatives
°ü·ÃÀÚ·á